Trials / Completed
CompletedNCT01668095
Biomarkers in Patients With Advanced Rhabdomyosarcoma
Developmental Pathway Drug-Targets in Advanced Rhabdomyosarcomas
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 10 (estimated)
- Sponsor
- Children's Oncology Group · Network
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This research trial studies tumor tissue to identify important proteins and biomarkers from patients with rhabdomyosarcoma that has spread to other places in the body and usually cannot be cured or controlled with treatment. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify biomarkers related to cancer.
Detailed description
PRIMARY OBJECTIVES: I. To investigate whether the expression of a subset of proteins (by immunohistochemistry), known to be Involved in the paired box (Pax)3, Pax7, and Patched-1 neuromuscular development pathways, are dysregulated in advanced and relapsed alveolar and embryonal rhabdomyosarcomas. OUTLINE: Immunohistochemistry is performed for each candidate target (Pax3, Pax7, and Patched-1) in each disease (alveolar, embryonal, and anaplastic rhabdomyosarcoma) for tissue microarray analysis.
Conditions
- Adult Rhabdomyosarcoma
- Childhood Alveolar Rhabdomyosarcoma
- Childhood Embryonal Rhabdomyosarcoma
- Previously Treated Childhood Rhabdomyosarcoma
- Recurrent Adult Soft Tissue Sarcoma
- Recurrent Childhood Rhabdomyosarcoma
- Stage III Adult Soft Tissue Sarcoma
- Stage IV Adult Soft Tissue Sarcoma
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Laboratory Biomarker Analysis | Correlative studies |
Timeline
- Start date
- 2012-08-01
- Primary completion
- 2012-10-01
- First posted
- 2012-08-17
- Last updated
- 2016-05-18
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01668095. Inclusion in this directory is not an endorsement.